Royalty Report: Drugs, Ophthalmological, Pharmaceuticals – Collection: 2377

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Ophthalmological
  • Pharmaceuticals
  • Delivery
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2377

License Grant
The Company hereby grants to the Licensee exclusive rights to register, import, market, sell and distribute the Products in the Territory.
License Property
The Company has developed among other things certain proprietary technology relating to non-surgical therapeutic ophthalmic systems

Products refers to Vitrase(TM) and Corneaplasty, certain proprietary technology relating to non-surgical therapeutic ophthalmic systems.

We are developing Vitrase, a proprietary formulation of hyaluronidase, for treatment of severe vitreous hemorrhage, a sight threatening condition, and diabetic retinopathy, the leading cause of adult blindness in the United States.  Vitrase is currently in two Phase III clinical trials for treatment of severe vitreous hemorrhage. We are also conducting a pilot Phase IIa clinical trial of Vitrase in Mexico for treatment of diabetic retinopathy.  Vitreous hemorrhage.  A vitreous hemorrhage occurs when retinal blood vessels rupture and bleed into the vitreous humor, the clear, gel-like substance that fills the back of the eye between the lens and the retina.  The blood from the hemorrhage can obscure vision and prevent ophthalmologists from seeing into the eye to diagnose or treat the cause of the hemorrhage.  The only current treatment options are a watchful waiting period, during which no medical treatment is provided in the hope that the hemorrhage will clear on its own, and an invasive surgical procedure to remove the blood filled vitreous humor from the eye.  Vitrase, when injected into the vitreous humor, causes the vitreous humor to liquefy and promotes clearance of vitreous hemorrhage.  Based on market research we commissioned in February 1999, we believe that approximately one million cases of vitreous hemorrhage occur each year in the United States, Europe and Japan and that approximately half of these cases are candidates for treatment using Vitrase.

Field of Use
The field of use apply to the treatment of the eye.

IPSCIO Record ID: 29275

License Grant
The Company, who develops miniaturized, injectable, drug delivery systems and the Licensee, amended and restated their February 2005 License and collaboration agreement relating to Iluvien, the company’s Phase III investigative treatment for diabetic macular edema, and certain other products.
License Property
Diabetic macular edema: is swelling of the retina in diabetes mellitus due to leaking of fluid from blood vessels within the macula.

The macula is the central portion of the retina, a small area rich in cones, the specialized nerve endings that detect color and upon which daytime vision depends.

Field of Use
Collaboration Field shall mean the treatment and prevention of eye diseases in humans; provided, however, that the treatment and prevention of [*] is excluded from the Collaboration Field.

IPSCIO Record ID: 27999

License Grant
The Agreement with the Licensee is structured so that the Licensor receives consideration based on its adjusted gross profit from its sales of Silicone Oil on a quarterly basis.
License Property
The Licensor operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of ophthalmic medical devices, ophthalmic pharmaceuticals and vascular devices.

Silicone oil is indicated for use as a prolonged retinal tamponade in selected cases of complicated retinal detachments when other interventions are not appropriate for patient management. Complicated retinal detachments or recurrent retinal detachments occur most commonly following perforating injuries or in eyes with proliferative vitreoretinopathy (PVR), proliferative diabetic retinopathy (PDR), cytomegalovirus (CMV) retinitis, or giant tears.
—Silicone oil is also indicated in the treatment of retinal detachments due to acquired immunodeficiency syndrome (AIDS)-related CMV retinitis and other viral infections.

Field of Use
Silicone Oils are insoluble in aqueous fluid and allow maintenance of retinal positioning for extended periods.

IPSCIO Record ID: 245932

License Grant
Exclusive License Grants. Licensor hereby grants to Licensee the following licenses:

(a) an exclusive license (even as to Licensor) in the Territory under the Licensor Patent Rights, and Program Patent Rights to research, develop, make, have made, use, offer to sell, sell, have sold, import and export the Products in the Field;
  
(b) an exclusive license (even as to Licensor) in the Territory under the Licensor Know-How, the Licensor Program Know-How, and Licensor’s rights in Joint Program Know-How to research, develop, make, have made, use, offer to sell, sell, have sold, import and export the Products in the Field; and

(c) an exclusive license (even as to Licensor) in the Territory under the Licensor Technology to research, develop, make, have made, use, offer to sell, sell, have sold, import and export the Surgical Instruments solely for use with, or in connection with the sale of, the Products in the Field.

Notwithstanding the license grants set forth above, Licensor shall retain those rights under the Licensor Technology that are necessary to perform Licensor’s obligations under the Research Program and the Feasibility Studies in accordance with Agreement and to manufacture and supply clinical supplies and commercial supply of Product to Licensee and the scale up and transfer of manufacturing capabilities to Licensee in accordance with this Agreement and the Supply Agreement.

Non-Exclusive License Grant. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee a non-exclusive, royalty-free license in the Territory under the Licensor Program Technology, for any and all uses, including without limitation, to research, develop, make, have made, use, offer to sell, sell, have sold, import and export a product other than the Products.

License Property
Product(s) shall mean TA Product(s), [KDRProduct(s)], Other [Target] Product(s), or Combination Product(s), individually or collectively, unless otherwise specified that is in final form (a) for sale by prescription, over-the-counter or any other method, or (b) for administration in a Clinical Trial or post-Marketing Authorization clinical trial.

TA Product shall mean the I-vation Platform incorporating a TA Compound as an active ingredient (which shall include without limitation the I-vation TA Product) and, for the purposes of Sections 5.2 through 5.6, that is in final form (i) for sale by prescription, over-the-counter or any other method, or (ii) for administration in a Clinical Trial or post-Marketing Authorization clinical trial.

I-vation Platform shall mean the Intravitreal Implant, together with the polymers applied as a coating thereto, for the purpose of containing and delivering sustained release of one or more active ingredients or therapeutic agents into the vitreous chamber of the eye, and any Improvements thereto,

Target shall mean a distinct, primary molecular target.

Surgical Instruments shall mean the Insertion Tool and/or the Extraction Tool, and any Improvements thereto.

Patent Rights shall mean any and all issued patents and patent applications in the Territory (which for the purposes of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention) and any divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, supplementary protection certificates, pediatric exclusivity periods, any other patent term extensions and exclusivity periods and the like of any such patents and patent applications, and any and all U.S. and foreign equivalents of the foregoing.

Licensor Technology shall mean the Patent Rights, Know-How, Program Technology, rights in Joint Programs and Inventions.and rights in Joint Patent Rights.

The I-vation Intravitreal Implant is a drug delivery system capable of delivering a variety of drugs on a sustained release basis for well over a year, can be implanted in a minimally invasive procedure, and may be removed once the drug has been fully released. Currently, the majority of treatments being developed for AMD and DME require repeated injections into the eye, often with a suboptimal drug dosing profile. Replacing multiple injections with a single implant providing long-term, controlled drug release could represent a significant advance in therapeutic treatment, including improved patient compliance, reduced side effects and greater efficacy.

I-vation TA (a version of the I-vation implant formulated with the steroid triamcinolone acetonide) is being studied in a Phase I human clinical trial called STRIDE (Sustained Triamcinolone Release for Inhibition of Diabetic Macular Edema). The trial is assessing the safety and tolerability of the I-vation(TM) Intravitreal Implant with triamcinolone acetonide (TA) in patients with Diabetic Macular Edema (DME) under an Investigational New Drug application with the U.S. Food and Drug Administration.

Field of Use
Field shall mean the treatment and/or prevention of any ocular disorder, including without limitation, diabetic macular edema (DME) and age related macular degeneration (AMD).

IPSCIO Record ID: 2934

License Grant
The Company entered into an Agreement to License certain patent technologies to a third party. The Company develops, manufactures and markets products for medical procedures that use embolotherapy.  Embolotherapy is the minimally invasive, image-guided therapeutic introduction of various biocompatible substances into a patient’s circulatory system to occlude a blood vessel, either to arrest or prevent hemorrhaging or to devitalize or destroy a structure by occluding its blood supply.  The Licensee is undisclosed.
Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.